01—Abstract
Summary
Summary of the 8-K filed November 29, 2022. Cited figures are marked; the original filing is the authoritative source.
CME Group Inc. (CME) filed a Form 8-K on November 29, 2022, to disclose upcoming pricing changes that will be effective February 1, 2023.
The company communicated these changes to its clients through a Special Executive Report. While the specifics of the pricing adjustments are not detailed within the 8-K filing itself, this announcement is a significant operational update for investors to note as it directly impacts revenue streams and client relationships. Investors should monitor subsequent communications from CME Group for further details regarding the nature and extent of these pricing changes.
The effective date of February 1, 2023, provides a clear timeline for these adjustments. This filing is primarily informational, intended to ensure timely disclosure to the market regarding material business updates.
02—Key points
Key Highlights
- CME Group announced pricing changes to its clients.
- The new pricing will be effective starting February 1, 2023.
- The announcement was made via a Special Executive Report (SER 9098).
- This information was disclosed through a Form 8-K filing on November 29, 2022.
- The filing is primarily for Regulation FD disclosure.
- Specific details of the pricing changes are not included in the 8-K.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to disclose upcoming pricing changes that CME Group is implementing for its clients, which will take effect on February 1, 2023. This is a required disclosure under Regulation FD to ensure timely and broad dissemination of material information.
When will the new pricing changes take effect?
The pricing changes announced by CME Group will be effective as of February 1, 2023.
Where can I find the details of the pricing changes?
This 8-K filing does not contain the specific details of the pricing changes. The company communicated these details to its clients via a Special Executive Report (SER 9098), which has been posted to CME Group's website.
Does this filing impact CME Group's financial statements?
This specific 8-K filing primarily concerns a Regulation FD disclosure about upcoming pricing changes and does not include updated financial statements. While the pricing changes themselves will eventually impact financial performance, this filing is an announcement of the change rather than a report of its financial impact.
04—Continue